マサチューセッツ州における急性リンパ性白血病の臨床試験
マサチューセッツ州内の拠点で、急性リンパ性白血病に関する15件の研究が参加者を募集しています。
マサチューセッツ州内の都市
公式研究テキスト（英語）
A Multicenter Study to Evaluate Next-Generation Sequencing (NGS) Testing and Monitoring of B-Cell Recovery to Guide Management Following Chimeric Antigen Receptor T-cell (CART) Induced Remission in Children and Young Adults With B Lineage Acute Lymph...
- Dana-Farber/Boston Children s Hospital, Boston
被験者募集中
1歳〜25歳 · 全性別 · 2026/10/02更新 · NCT05621291Inotuzumab Ozogamicin Post-Transplant For Acute Lymphocytic Leukemia
- Dana-Farber Cancer Institute, Boston
被験者募集中第1/2相
16歳〜75歳 · 全性別 · 2026/09/10更新 · NCT03104491The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
- Dana-Farber Cancer Institute, Boston
被験者募集中第1/2相
22歳以下 · 全性別 · 2026/08/25更新 · NCT04726241ALL Backbone in AYAs
- Dana Farber Cancer Institute, Boston
被験者募集中第2相
18歳〜51歳 · 全性別 · 2026/08/17更新 · NCT07227584Safety Study to Evaluate the Occurrence of EFAD in Pediatric Patients With PNAC Who Require More Than Eight Weeks of Omegaven Treatment
- Children's Hospital Corporation d/b/a Boston Children's Hospital, Boston
被験者募集中観察研究
1 Day – 17 Years · 全性別 · 2026/08/14更新 · NCT06274788A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant
- Brigham and Women's Hospital, Boston
被験者募集中第1相健康なボランティア歓迎
18歳〜75歳 · 全性別 · 2026/07/28更新 · NCT07020533A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
- Tufts Medical Center, Boston
- Beth Israel Deaconess, Boston
- Dana Farber Cancer Institute, Boston
被験者募集中観察研究
全年齢 · 全性別 · 2026/07/06更新 · NCT01351545Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment
- Dana-Farber Cancer Institute, Boston
被験者募集中観察研究
全年齢 · 全性別 · 2026/05/18更新 · NCT01790152Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
- Dana Farber Cancer Institute, Boston
被験者募集中第1相
13歳以上 · 全性別 · 2026/05/05更新 · NCT04771572A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
- Massachusetts General Hospital, Boston
被験者募集中第1/2相
12歳以上 · 全性別 · 2026/03/24更新 · NCT04988555A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
- Dana-Farber Cancer Institute, Boston
被験者募集中第2相
18歳〜66歳 · 全性別 · 2026/03/17更新 · NCT06859424Venetoclax Basket Trial for High Risk Hematologic Malignancies
- Dana-Farber Cancer Institute, Boston
被験者募集中第1相
1歳〜40歳 · 全性別 · 2026/03/12更新 · NCT05292664CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant
- DFCI/BWH Brigham and Women's Hospital, Boston
被験者募集中第2相健康なボランティア歓迎
18歳〜75歳 · 全性別 · 2026/03/10更新 · NCT06059391Prevention of GvHD in Participants With Hematological Malignancies Undergoing Hematopoietic Stem Cell Transplant (HSCT)
- Dana-Farber Cancer Institute, Boston
被験者募集中第1相
18歳以上 · 全性別 · 2025/04/15更新 · NCT06462365Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
- Dana-Farber Cancer Institute, Boston
被験者募集中第1相
1歳〜21歳 · 全性別 · 2024/12/06更新 · NCT05476770ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。